Comparative Pharmacology
Head-to-head clinical analysis: ALDOCLOR 250 versus MICARDIS HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDOCLOR 250 versus MICARDIS HCT.
ALDOCLOR-250 vs MICARDIS HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.
250 mg orally twice daily
One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.
None Documented
None Documented
1.5-3 hours; prolonged in renal impairment (up to 20 hours with CrCl <10 mL/min).
Telmisartan: terminal half-life ≈24 hours, allowing once-daily dosing. Hydrochlorothiazide: 6-15 hours (mean 10 hours).
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 mL/min.
Primarily biliary excretion (≈60%) and renal excretion (≈40%) as unchanged drug. Telmisartan: renal <1%, fecal >97%. Hydrochlorothiazide: renal >95% unchanged.
Category C
Category C
Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic)
Antihypertensive Combination (ARB + Thiazide Diuretic)